Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma: Further explanation of a dose-escalating pilot study conducted primarily to consider the safety of this pharmacological modification

British Journal of Dermatology

Volumn 162, Issue 1, 2010, Pages 224-225

  Curnow, A ^a   Campbell, S M ^a  

^a ROYAL CORNWALL HOSPITAL   (United Kingdom)

Author keywords

Basal cell carcinoma; CP94; Hydroxypyridinone; Iron chelating agent; Photodynamic therapy

Indexed keywords

1,2 DIETHYL 3 HYDROXY 4 PYRIDONE;

BASAL CELL CARCINOMA; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG SAFETY; FEASIBILITY STUDY; HUMAN; IRON CHELATION; LETTER; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; TOPICAL TREATMENT;

CARCINOMA, BASAL CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IRON CHELATING AGENTS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PILOT PROJECTS; PYRIDONES; SKIN NEOPLASMS;

EID: 72749091995     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2009.09544.x     Document Type: Letter

References (2)

1. Mangano A, Albertin A, La Colla L. Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma: when statistics make a difference. Br J Dermatol 2008 161 : 215 216.
2. Campbell SM, Morton CA, Alyahya R et al. Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma. Br J Dermatol 2008 159 : 387 393.